{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:38:08Z","timestamp":1760852288826,"version":"3.37.3"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1124\/dmd.106.014266","type":"journal-article","created":{"date-parts":[[2007,3,15]],"date-time":"2007-03-15T00:31:14Z","timestamp":1173918674000},"page":"884-897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Metabolism, Pharmacokinetics, and Excretion of the Substance P Receptor Antagonist CP-122,721 in Humans: Structural Characterization of the Novel Major Circulating Metabolite 5-Trifluoromethoxy Salicylic Acid by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and NMR Spectroscopy"],"prefix":"10.1016","volume":"35","author":[{"given":"Kevin","family":"Colizza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.106.014266_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1021\/jm00259a009","article-title":"Mass spectral analysis of glucuronides","volume":"16","author":"Billets","year":"1973","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.106.014266_bib2","series-title":"The 52nd American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, Nashville, TN, 23-27 May, 2004.","article-title":"Characterization of in vivo metabolites of the potent tachykinin NK1 receptor antagonist, CP-122,721 in Humans by HPLC\/RAM\/ESI\/MS\/MS","author":"Colizza","year":"2004"},{"key":"10.1124\/dmd.106.014266_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1124\/jpet.301.2.536","article-title":"Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists","volume":"301","author":"Duffy","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.014266_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.1981.56","article-title":"Determination of mean valproic acid serum level by assay of a single pooled sample","volume":"29","author":"Hamilton","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.014266_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00023210-200519040-00001","article-title":"Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential","volume":"19","author":"Herpfer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1124\/dmd.106.014266_bib6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.106.014266_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/00498250600594444","article-title":"Metabolism, pharmacokinetics and excretion of a potent tachykinin NK1 receptor antagonist (CP-122,721) in rat: characterization of a novel oxidative pathway","volume":"36","author":"Kamel","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.106.014266_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-4347(97)00315-0","article-title":"Determination of the substance P receptor antagonist CP-122,721 in plasma by narrow-bore high-performance liquid chromatography-ionspray tandem mass spectrometry","volume":"700","author":"Kamel","year":"1997","journal-title":"J Chromatogr Biomed Appl"},{"key":"10.1124\/dmd.106.014266_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0009-2797(99)00163-5","article-title":"Difference of the liver and kidney in glycine conjugation of ortho-substituted benzoic acids","volume":"125","author":"Kasuya","year":"2000","journal-title":"Chem-Biol Interact"},{"key":"10.1124\/dmd.106.014266_bib10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0090-9556(25)08623-4","article-title":"Isolation and characterization of carbinolamide and phenolic glucuronide conjugates of (\u00b1)-N-methyl-N-(1-methyl-3,3-diphenylpropyl) formamide and N-formylmethamphetamine by FAB\/MS, LC\/MS\/MS, and NMR","volume":"20","author":"Mutlib","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014266_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1254\/jphs.FPJ04035X","article-title":"Diphenidol has no actual broad antiemetic activity in dogs and ferrets","volume":"96","author":"Nakayama","year":"2004","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/dmd.106.014266_bib12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1021\/ac025934f","article-title":"On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development","volume":"75","author":"Nassar","year":"2003","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.106.014266_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1023\/A:1015875800846","article-title":"Determination of the relative formation and elimination clearance of two major carbamazepine metabolites in humans: a comparison between traditional and pooled sample analysis","volume":"8","author":"Riad","year":"1991","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.106.014266_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1021\/es049466y","article-title":"Aerobic biotransformation of 14C-labeled 8-2 telomer B alcohol by activated sludge from a domestic sewage treatment plant","volume":"39","author":"Wang","year":"2005","journal-title":"Environ Sci Tech"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624013138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624013138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.106.014266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:03:18Z","timestamp":1739894598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624013138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0090955624013138"],"URL":"https:\/\/doi.org\/10.1124\/dmd.106.014266","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism, Pharmacokinetics, and Excretion of the Substance P Receptor Antagonist CP-122,721 in Humans: Structural Characterization of the Novel Major Circulating Metabolite 5-Trifluoromethoxy Salicylic Acid by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and NMR Spectroscopy","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.106.014266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}